Eloxx Pharmaceuticals KOL even discussed Phase 2 results of ELX-02

Eloxx Pharmaceuticals highlighted its recently held key opinion leader, KOL, event discussing the significant unmet medical need of patients with Alport syndrome and presented additional topline results from its Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome. Eloxx provided topline data for 8-weeks of treatment for the third patient in the study and data after 4, and 8-weeks after end of treatment in all three patients that have completed treatment. The rapid increase in UPCR after end of treatment in one patient who achieved remission during the trial provides additional evidence of biological activity of ELX-02 in this population. As observed in prior clinical studies, ELOX-02 was well tolerated in this trial. Based on these results, Eloxx intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations. “We were delighted to bring more attention to the debilitating unmet medical needs of Alport syndrome patients during this event,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. “Further, we are extremely encouraged by the findings from our Phase 2 trial of ELOX-02 for the treatment of Alport syndrome in patients with nonsense mutations and look forward to advancing this program into a pivotal open label study, pending obtaining the necessary capital.”